



Surge in side effects such as hypertension and diabetes are pushing the market ahead”

Polaris Market Research

handling their blood glucose levels. Recently, clinical trial statistics displayed these medicines were also of assistance in enhancing kidney and heart well-being for people with CKD or heart failure in spite of not having diabetes. The growing existence of diabetes caused a notable usage of SGLT2 inhibitors for the cure of type 2 diabetes, impacting the Europe SGLT2 inhibitors market demand favourably.

Key Market Statistics:

- The Europe SGLT2 inhibitors market size was valued at USD 4,241.98 million in 2023 and is projected to grow to USD 7,629.79 million by 2032.
- The growing load of detrimental illnesses fuels the need for SGLT2 inhibitors in Europe.
- The market segmentation is primarily based on indication, drug, distribution channel, and country.
- The study provides market insights into Germany, France, the UK, Italy, Spain, Netherlands, Russia, and the rest of Europe.

Market Dynamics:

The Europe SGLT2 inhibitors market is portrayed by aggressiveness. Spearheading market contenders fund massively in research and development to augment their product lines which drives the market growth. Market contenders are also shouldering an assortment of tactical ventures to augment their footprint, covering the region with crucial market advancements such as contemporary product instigations, mergers and acquisitions, elevated funding, and associations with other firms.

Key Players:

Understanding key players and their initiatives provides valuable insights into the competitive landscape and emerging opportunities in the market. Here are the top companies in the market:

- AstraZeneca
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novo Nordisk
- Sanofi

- Pfizer Inc.

□□□□ □□□ □□□□ □□ □□ □□□□ □□□□□□ □□□□□□□□□□□□:

- In May 2024, Lexicon declared its scheme to reintroduce its New Drug Application (NDA) for Zynquista to the FDA by mid-2024, succeeding a failed attempt to acquire acceptance for type 1 diabetes in 2019.
- In March 2024, Novo Nordisk declared its plan to look for administrative consent for augmented Ozempic labels in the US and EU in 2024.

□□□□□□□ □□□ □ □□□□□□□□ □□ □□□□ □□□□□□ □□□□□□ □□□□□□□□:

https://www.polarismarketresearch.com/industry-analysis/europe-sgl2-inhibitors-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

□□□□□□ □□□□□□ □□ □□□□□□□□□□□□:

Rising Urbanization: The escalating urbanization has caused elevated subjection to strain, contamination, and reduced physical exercise, which has contributed to elements such as detrimental illnesses fueling the Europe SGLT2 inhibitors market growth. Specific occupations also involve subjection to detrimental materials and elevated strain levels, thereby escalating the susceptibility to detrimental illnesses.

Growing Elderly Population: The population of England and Wales with Census 2021 signifies an elevated aggregate of persons in age categories. Over 11 million people, reckoning for 18.6% of the absolute population, were around 65 years and above, contrasted to 16.4% in 2011.

Increasing Government Initiatives: European governments are applying several estimates, such as offering allotment for diabetes medicines, enhancing the healthcare approach, and highlighting prohibitive care. These schemes assist improve diabetes care and handling which could cause extensive acquisition of SGLT2 inhibitors.

□□□□□□□ □□□□□□□:

Germany is anticipated to witness a significant CAGR from 2024 to 2032. The country's robust growth is due to the National Health Service in the country, which has a robust framework and substantial availability, easing the extensive obtainability of progressive diabetes cures such as SGLT2 inhibitors.

The UK accounted for the largest share of the Europe SGLT2 inhibitors market in 2023. This is primarily because of the existence of the spearheading pharmaceutical firms and continuing research and development ventures that have braced the obtainability and acquisition of SGLT2 inhibitors in the country.

□□□□□□ □□□ □□□□ □□□ □□□□□ □□□□□ □□□□□□□:

<https://www.polarismarketresearch.com/industry-analysis/europe-sgl2-inhibitors->

[market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01](https://www.researchandmarkets.com/Market/Inquire-Before-Buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

□□□□□□□□ □□□□□□□□:

By Indication Outlook

- Cardiovascular
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes
- Others

By Drug Outlook

- Farxiga (Dapagliflozin)
- Inpefa (Sotagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other SGLT2 Inhibitors

By Distribution Channel Outlook

- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

By Country Outlook

- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe

□□□□:

How much is the Europe SGLT2 inhibitors market?

The market size was valued at USD 4,241.98 million in 2023 and is projected to grow to USD 7,629.79 million by 2032.

What does the Europe SGLT2 inhibitors market cover?

The market covers revenue forecast, market competitive landscape, growth factors, and trends.

What are the segments covered by the market?

The market covers segments such as by indication, drug, distribution channel, and country.

What is the growth rate of the market?

The market is projected to register a CAGR of 6.7% during 2024–2032.

Polymers Market 2023-2032 | Global Market Research and Consulting Company

[Polymers Market 2023-2032 | Global Market Research and Consulting Company](#) provides comprehensive market intelligence, including market size, growth rate, and key players. The report covers the market from 2023 to 2032, offering insights into market trends, challenges, and opportunities. It also includes a detailed analysis of the competitive landscape and the impact of various factors on the market's performance.

Personalized Medicine Biomarkers Market:

Personalized Medicine Biomarkers Market:

<https://www.polarismarketresearch.com/industry-analysis/personalized-medicine-biomarkers-market>

Medical Device Engineering Market:

<https://www.polarismarketresearch.com/industry-analysis/medical-device-engineering-market>

Patient Support Technology Market:

<https://www.polarismarketresearch.com/industry-analysis/patient-support-technology-market>

Gastrointestinal Products Market:

<https://www.polarismarketresearch.com/industry-analysis/gastrointestinal-products-market>

Laparoscopic Retrieval Bag Market:

<https://www.polarismarketresearch.com/industry-analysis/laparoscopic-retrieval-bag-market>

Polymers Market 2023-2032 | Global Market Research and Consulting Company

Polymers Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+ +1 929-297-9727

sales@polarismarketresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/776522521>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.